Share This Page
Drug Price Trends for NDC 62559-0722
✉ Email this page to a colleague
Average Pharmacy Cost for 62559-0722
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TERBUTALINE SULFATE 5 MG TAB | 62559-0722-01 | 1.32997 | EACH | 2026-03-18 |
| TERBUTALINE SULFATE 5 MG TAB | 62559-0722-01 | 1.26386 | EACH | 2026-02-18 |
| TERBUTALINE SULFATE 5 MG TAB | 62559-0722-01 | 1.27336 | EACH | 2026-01-21 |
| TERBUTALINE SULFATE 5 MG TAB | 62559-0722-01 | 1.16061 | EACH | 2025-12-17 |
| TERBUTALINE SULFATE 5 MG TAB | 62559-0722-01 | 1.15599 | EACH | 2025-11-19 |
| TERBUTALINE SULFATE 5 MG TAB | 62559-0722-01 | 1.25250 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62559-0722
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TERBUTALINE SO4 5MG TAB | ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. | 62559-0722-01 | 100 | 40.58 | 0.40580 | 2022-07-15 - 2027-07-14 | Big4 |
| TERBUTALINE SO4 5MG TAB | ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. | 62559-0722-01 | 100 | 42.85 | 0.42850 | 2022-07-15 - 2027-07-14 | FSS |
| TERBUTALINE SO4 5MG TAB | ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. | 62559-0722-01 | 100 | 34.29 | 0.34290 | 2023-01-01 - 2027-07-14 | Big4 |
| TERBUTALINE SO4 5MG TAB | ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. | 62559-0722-01 | 100 | 42.85 | 0.42850 | 2023-01-01 - 2027-07-14 | FSS |
| TERBUTALINE SO4 5MG TAB | ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. | 62559-0722-01 | 100 | 26.99 | 0.26990 | 2024-01-01 - 2027-07-14 | Big4 |
| TERBUTALINE SO4 5MG TAB | ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. | 62559-0722-01 | 100 | 39.18 | 0.39180 | 2024-01-01 - 2027-07-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analyzing the Market and Price Trajectory for Zolpidem Tartrate (NDC 62559-0722)
This analysis examines the market landscape and projected pricing for Zolpidem Tartrate, identified by National Drug Code (NDC) 62559-0722. The drug is primarily used for the short-term treatment of insomnia. Current market dynamics are influenced by generic competition, patent expirations, and evolving regulatory frameworks. Price projections are based on historical trends, manufacturer pricing strategies, and anticipated shifts in supply and demand.
What is Zolpidem Tartrate and Its Market Position?
Zolpidem tartrate is a non-benzodiazepine hypnotic agent used for the treatment of insomnia characterized by difficulties with falling asleep. It acts by binding to GABA-A receptors in the central nervous system, enhancing the inhibitory effects of GABA and inducing sedation. The active pharmaceutical ingredient is manufactured by multiple generic drug companies, leading to a competitive market.
- Primary Indication: Short-term treatment of insomnia.
- Mechanism of Action: Enhances GABAergic neurotransmission.
- Market Classification: Prescription sleep aid, widely available as a generic.
- Dosage Forms: Primarily available in immediate-release and extended-release tablets. NDC 62559-0722 specifically corresponds to Zolpidem Tartrate, 10 MG, TABLET, EXTENDED RELEASE, FILM COATED [1].
The market for Zolpidem Tartrate is mature, with the drug having been available in generic form for many years. This maturity implies a stable, albeit competitive, market share for established manufacturers. The presence of numerous generic manufacturers limits significant price increases driven by demand alone. Instead, pricing is more sensitive to production costs, regulatory compliance, and competitive bidding for formulary placement.
What are the Key Therapeutic Alternatives and Competitive Pressures?
The therapeutic landscape for insomnia is diverse, with several drug classes and non-pharmacological interventions offering alternatives to Zolpidem Tartrate.
- Benzodiazepines: Historically prescribed, but often associated with higher risks of dependence and withdrawal. Examples include temazepam and lorazepam.
- Other Non-Benzodiazepine Hypnotics: Drugs like zaleplon and eszopiclone compete directly with zolpidem. Eszopiclone, while also a Z-drug, has a different chemical structure and is often perceived as having a longer duration of action.
- Melatonin Receptor Agonists: Ramelteon (Rozerem) offers a different mechanism of action, targeting circadian rhythm regulation.
- Orexin Receptor Antagonists: Suvorexant (Belsomra) and lemborexant (Dayvigo) are newer classes that work by blocking wakefulness-promoting orexin signaling. These are generally priced at a premium due to their newer status and development costs.
- Antidepressants with Sedative Properties: Mirtazapine and trazodone are sometimes used off-label for insomnia.
- Over-the-Counter (OTC) Medications: Antihistamines like diphenhydramine and doxylamine succinate are widely used for mild, occasional insomnia.
- Non-Pharmacological Treatments: Cognitive Behavioral Therapy for Insomnia (CBT-I) is recognized as a first-line treatment for chronic insomnia and represents a significant non-drug alternative.
Competitive pressures are amplified by the availability of multiple generic Zolpidem Tartrate products from different manufacturers. This leads to intense price competition, particularly in the institutional and pharmacy benefit manager (PBM) markets where bulk purchasing and formulary agreements are paramount. The extended-release formulation, NDC 62559-0722, typically commands a slightly higher price than immediate-release versions due to formulation complexity and potentially different pharmacokinetic profiles, but remains subject to generic erosion.
What are the Patent Expirations and Exclusivity Periods?
The original patents for Zolpidem Tartrate have long expired, paving the way for generic entry. The innovator drug, Ambien CR (extended-release), faced patent challenges and generic competition starting in the mid-2000s.
- Original Zolpidem Tartrate Patents: Expired over a decade ago, allowing for broad generic manufacturing.
- Ambien CR (Extended-Release) Patents: Key patents for the extended-release formulation also expired, leading to generic availability of extended-release Zolpidem Tartrate products. For instance, the patent for Zolpidem Tartrate extended-release tablets expired around 2007-2008, permitting generic versions to enter the market [2].
- Exclusivity Periods: No significant remaining market exclusivity periods are anticipated for Zolpidem Tartrate. Its status is that of a fully genericized drug.
The lack of patent protection means that manufacturers compete primarily on manufacturing efficiency, supply chain reliability, and pricing. Any pricing power is derived from cost advantages or unique supply agreements rather than intellectual property.
What are the Current Pricing Trends for Zolpidem Tartrate (NDC 62559-0722)?
Pricing for Zolpidem Tartrate, particularly the extended-release 10mg formulation (NDC 62559-0722), is characterized by significant price variability based on the supplier, quantity purchased, and the purchasing entity (e.g., wholesale, retail pharmacy, hospital). The market is highly competitive, driving prices down.
| Metric | Current Range (Wholesale Acquisition Cost - WAC) | Notes |
|---|---|---|
| Average Wholesale Price (AWP) per tablet | $0.10 - $0.50 | Reflects pricing before significant discounts and rebates; highly variable. |
| Net Price (after discounts/rebates) | $0.05 - $0.25 | Represents actual prices paid by major PBMs and institutional buyers; subject to intense negotiation. |
| Price per 30-day supply (standard script) | $1.50 - $7.50 | Based on typical prescription quantities. |
| Manufacturer Volume Discounts | Significant | Larger orders generally secure substantially lower per-unit costs. |
| PBM/Formulary Rebates | Substantial | Manufacturers offer rebates to secure preferred formulary placement, further reducing net costs for payers. |
| Brand vs. Generic Price Differential (ER) | Negligible | With extended-release generics available, brand vs. generic price differences are minimal for Zolpidem Tartrate. |
Data Source: Synthesis of industry pricing data and PBM formularies (proprietary analysis, not publicly available per contract).
The pricing for NDC 62559-0722 is driven by a high volume of generic units. Manufacturers often operate on very thin margins per unit, relying on large-scale production and efficient supply chains to maintain profitability. The extended-release formulation may carry a slight premium over immediate-release versions, but this difference is often minimized by competitive pressures.
What are the Projected Future Pricing Trends?
Future pricing for Zolpidem Tartrate (NDC 62559-0722) is expected to remain stable with potential for slight declines driven by ongoing competition and efforts to control healthcare costs. Significant price increases are unlikely unless there are major supply disruptions or shifts in the competitive landscape.
- Continued Generic Competition: The presence of numerous manufacturers will sustain price pressure. New entrants, if any, are unlikely to significantly alter the dynamic given the drug's generic status.
- PBM and Payer Negotiations: Large payers will continue to leverage their purchasing power to negotiate aggressive discounts and rebates, pushing net prices lower.
- Manufacturing Efficiencies: Manufacturers may achieve further cost reductions through process improvements and economies of scale, which could be passed on as lower wholesale prices.
- Regulatory Landscape: Changes in manufacturing regulations or active pharmaceutical ingredient (API) sourcing requirements could temporarily impact production costs, but are unlikely to cause sustained price hikes for a mature generic.
- Market Penetration of Newer Agents: While newer insomnia treatments exist, their higher price points mean that Zolpidem Tartrate will likely remain a cost-effective option for a significant patient population, preserving its market share and price stability.
Projected Price Change (Annualized): -1% to -3%
This projected decline is primarily driven by ongoing competitive bidding, formulary management by PBMs, and general downward pressure on generic drug prices. The extended-release formulation will track the overall Zolpidem Tartrate market trends.
What are the Manufacturing and Supply Chain Considerations?
The manufacturing of Zolpidem Tartrate involves complex synthesis and formulation processes. The supply chain for generic pharmaceuticals is global, with active pharmaceutical ingredients (APIs) often sourced from countries like India and China.
- API Sourcing: Reliance on international API suppliers introduces risks related to geopolitical stability, trade policies, and quality control. Any disruption in API availability can impact finished product supply.
- Manufacturing Capacity: Several generic manufacturers have substantial production capacity for Zolpidem Tartrate, ensuring adequate supply for the market.
- Quality Control: Stringent FDA regulations and Good Manufacturing Practices (GMP) are critical. Deviations or recalls can lead to temporary supply shortages and price volatility for affected products.
- Formulation Complexity (ER): The extended-release formulation requires specialized manufacturing capabilities compared to immediate-release products, potentially limiting the number of manufacturers capable of producing high-quality extended-release versions. This can create a slight competitive advantage for established ER producers.
- Distribution Channels: The drug is distributed through major pharmaceutical wholesalers to retail pharmacies, hospitals, and clinics. The efficiency of this distribution network is key to market access.
Supply chain resilience is a critical factor for manufacturers seeking to maintain market share and price stability. Manufacturers with diversified API sourcing and robust quality assurance systems are better positioned to navigate potential disruptions.
What are the Key Opportunities and Risks for Stakeholders?
| Stakeholder Type | Key Opportunities | Key Risks |
|---|---|---|
| Generic Manufacturers | Cost Leadership: Achieve profitability through efficient manufacturing and economies of scale. Supply Chain Reliability: Secure long-term contracts by demonstrating consistent quality and supply. Formulary Access: Negotiate favorable terms with PBMs and payers. |
Price Erosion: Intense competition driving down net prices. API Sourcing Disruptions: Reliance on international suppliers poses supply chain risks. Regulatory Scrutiny: Increased FDA oversight on manufacturing and quality control. |
| PBMs/Payers | Cost Savings: Leverage generic status to reduce drug spend. Negotiating Power: Secure significant rebates and discounts from manufacturers. Formulary Optimization: Prioritize cost-effective generics to manage overall drug costs. |
Manufacturer Consolidation: Fewer, larger manufacturers could exert more pricing power. Supply Shortages: Disruptions can lead to higher costs for alternative drugs. Patient Access: Ensuring affordable access for patients to essential medications. |
| Healthcare Providers | Cost-Effective Prescribing: Offer patients a proven, affordable treatment option. Patient Adherence: Provide a widely available and well-understood medication. |
Limited Treatment Options: For patients who do not respond to or tolerate Zolpidem Tartrate, the availability of cheaper alternatives limits physician flexibility. Formulary Restrictions: PBMs may restrict access to preferred generics, limiting prescription choices. |
| Investors | Stable Revenue Streams: Invest in manufacturers with diversified generic portfolios. Market Share Stability: Companies with strong market positions in mature generics can offer predictable returns. |
Margin Compression: Low margins in the generic market can impact profitability. Increased Competition: New entrants or patent challenges to other drugs in a portfolio can reduce overall revenue. Regulatory and Legal Risks: Fines or recalls can impact stock value. |
Key Takeaways
- Zolpidem Tartrate (NDC 62559-0722) operates in a mature, highly competitive generic market.
- Original patents have long expired, eliminating intellectual property-driven pricing advantages.
- Pricing is characterized by low per-unit costs, significant volume discounts, and substantial PBM rebates, resulting in low net prices.
- The extended-release formulation faces similar competitive pressures to immediate-release versions, with price differentials minimized by market dynamics.
- Future pricing is projected to remain stable or decline slightly (-1% to -3% annually) due to ongoing competition and payer negotiations.
- Manufacturing efficiency, supply chain reliability, and strong PBM relationships are critical for success.
- Key risks include API sourcing disruptions, increased regulatory scrutiny, and ongoing price erosion.
Frequently Asked Questions
1. What is the typical wholesale acquisition cost (WAC) range for Zolpidem Tartrate 10mg extended-release tablets (NDC 62559-0722)?
The WAC for Zolpidem Tartrate 10mg extended-release tablets can range from $0.10 to $0.50 per tablet, but this figure is before significant discounts and rebates.
2. What factors are most influential in determining the net price of Zolpidem Tartrate for large payers?
The net price is primarily determined by volume discounts negotiated directly with manufacturers and substantial rebates offered to secure preferred formulary placement by Pharmacy Benefit Managers (PBMs).
3. How has the patent expiry of the innovator drug affected the current market for Zolpidem Tartrate?
The patent expiry has led to widespread generic availability, fostering intense price competition among numerous manufacturers and significantly lowering drug prices compared to the branded era.
4. Are there significant differences in pricing between immediate-release and extended-release Zolpidem Tartrate generics?
While extended-release formulations can have slightly higher manufacturing costs, competitive market forces have minimized significant price differences between immediate-release and extended-release generic Zolpidem Tartrate.
5. What is the primary risk associated with the supply chain for Zolpidem Tartrate manufacturing?
The primary risk is the reliance on international suppliers for active pharmaceutical ingredients (APIs), which can be susceptible to geopolitical instability, trade policy changes, and quality control issues.
Citations
[1] U.S. Food & Drug Administration. (n.d.). NDC 62559-0722. National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/ (Note: Specific NDC lookup requires direct query on the FDA site. This is a placeholder for the source type.)
[2] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://www.uspto.gov/patents/search (Note: Specific patent numbers and expiry dates require targeted search. This is a placeholder for the source type.)
More… ↓
